KPV

KPV (Lysine-Proline-Valine) is the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), a potent anti-inflammatory peptide acting via melanocortin receptors (MC1R/MC3R). Orally stable, it’s researched for IBD, psoriasis, wounds, and allergies—reducing cytokines 50–80% without steroids’ sides. 3-amino-acid structure ensures gut penetration.

Key: MC1R agonism → ↓NF-κB, TNF-α, IL-6; ↑IL-10 resolution.

How It Works

Cytokine Suppression: Blocks inflammatory cascades.
Immune Balance: T-reg ↑, Th17 ↓.
Barrier Repair: Tight junctions, mucosa integrity.
Antimicrobial: Melanocortin pathways vs. pathogens.

Pharmacokinetics: Oral > subQ; half-life ~30min; systemic despite small size.

Research Evidence

Application	Key Studies/Effects
IBD/Colitis	80% colon damage reduction (mice, J Pharmacol Exp Ther 2010).
Psoriasis	Lesion clearance, TNF-α ↓70% (topical models).
Wounds	Healing 2x faster, ↓scarring (rat burns).
Allergies	Anaphylaxis prevention (MC1R KO studies).
Long-COVID	Cytokine storm analogs (prelim).

Human: Compassionate IBD use; oral capsules in trials.

Protocols (Research Contexts)

Goal	Dose (mg/day)	Route/Frequency	Cycle
Gut Health (IBD)	1–5mg	Oral daily	4–12 weeks
Skin (Psoriasis)	0.5–2mg	Oral + topical	8 weeks
Wounds	1–3mg	Oral + local	Until healed
Inflammation	0.5–1mg	2–3x/day	PRN

Stack: w/ BPC-157 (gut repair), GHK-Cu (skin).
Form: Oral caps, nasal, cream.

Benefits Breakdown

Gut Healing: UC/CD remission-like.
Skin Conditions: Eczema, acne inflammation ↓.
Allergy/Asthma: Mast cell stabilization.
Post-Viral: Long-haul inflammation.
Wellness: Systemic cytokine control.

Side Effects & Safety

Common (Rare)	Notes	Mitigation
Mild nausea	MC1R pigmentation (low)	Dose-dependent
None major	Immunosuppression? (no)	Clean profile

Tox: LD50 >500mg/kg; pregnancy caution.

Comparisons

Peptide	Anti-Inflam Target	Oral Stable?	Best For
KPV	MC1R/NF-κB	Yes	Gut/Skin
BPC-157	VEGF/Cytokines	Yes	Repair
Thymosin A1	Immune	Inj	Viral
VIP	VIPR	Partial	Neuro-inflam

Status & Outlook

Research Chemical: Oral formulations advancing.
Trials: IBD Phase 2 (Integrative Peptides).
UK: Research/clinic use.

Disclaimer: Research-only; MD oversight.

Reviews

There are no reviews yet.

KPV

KPV